166 related articles for article (PubMed ID: 32859699)
1. Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial.
Nicolay NH; Rühle A; Wiedenmann N; Niedermann G; Mix M; Weber WA; Baltas D; Werner M; Kayser G; Grosu AL
J Nucl Med; 2021 Apr; 62(4):471-478. PubMed ID: 32859699
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
Rühle A; Grosu AL; Wiedenmann N; Stoian R; Haehl E; Zamboglou C; Baltas D; Werner M; Kayser G; Nicolay NH
Radiother Oncol; 2021 Jun; 159():75-81. PubMed ID: 33753155
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.
Rühle A; Wiedenmann N; Fennell JT; Mix M; Ruf J; Stoian R; Thomsen AR; Vaupel P; Baltas D; Grosu AL; Nicolay NH
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1650-1660. PubMed ID: 34773163
[TBL] [Abstract][Full Text] [Related]
5. FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Bandurska-Luque A; Löck S; Haase R; Richter C; Zöphel K; Abolmaali N; Seidlitz A; Appold S; Krause M; Steinbach J; Kotzerke J; Zips D; Baumann M; Troost EGC
Radiother Oncol; 2019 Jan; 130():97-103. PubMed ID: 30293643
[TBL] [Abstract][Full Text] [Related]
6. Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.
Nicolay NH; Wiedenmann N; Mix M; Weber WA; Werner M; Grosu AL; Kayser G
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1046-1055. PubMed ID: 31811344
[TBL] [Abstract][Full Text] [Related]
7. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
8. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
9. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
[TBL] [Abstract][Full Text] [Related]
10. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.
Rischin D; Hicks RJ; Fisher R; Binns D; Corry J; Porceddu S; Peters LJ;
J Clin Oncol; 2006 May; 24(13):2098-104. PubMed ID: 16648512
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
[TBL] [Abstract][Full Text] [Related]
13. Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer.
Zschaeck S; Zöphel K; Seidlitz A; Zips D; Kotzerke J; Baumann M; Troost EGC; Löck S; Krause M
Radiother Oncol; 2021 Feb; 155():204-211. PubMed ID: 33252044
[TBL] [Abstract][Full Text] [Related]
14. Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
Zschaeck S; Löck S; Hofheinz F; Zips D; Saksø Mortensen L; Zöphel K; Troost EGC; Boeke S; Saksø M; Mönnich D; Seidlitz A; Johansen J; Skripcak T; Gregoire V; Overgaard J; Baumann M; Krause M
Radiother Oncol; 2020 Aug; 149():189-196. PubMed ID: 32417350
[TBL] [Abstract][Full Text] [Related]
15. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
F1000Res; 2020; 9():1350. PubMed ID: 33796277
[No Abstract] [Full Text] [Related]
16. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent.
Hicks RJ; Rischin D; Fisher R; Binns D; Scott AM; Peters LJ
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1384-91. PubMed ID: 16133382
[TBL] [Abstract][Full Text] [Related]
17. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
[TBL] [Abstract][Full Text] [Related]
20. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
